Biotech - Press Releases

Date	Title	Company
06-Dec-2022	Immutep announces GMP manufacturing process developed for IMP761, a first-in-class LAG-3 agonist for autoimmune disease	Immutep
06-Dec-2022	Evaxion and ExpreS²ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate	Evaxion Biotech
06-Dec-2022	Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022	Molecure
06-Dec-2022	Alfa Chemistry Diversifies Its Chemical Supply by Adding Luminescent Materials, Biomedical Polymers, and Electroplating Intermediates	Alfa Chemistry
02-Dec-2022	Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants	Almirall
02-Dec-2022	VPM1002 Vaccination as Prophylaxis Against Severe Respiratory Infectious Diseases	VPM1002 Vaccination as Prophylaxis Against Severe Respiratory Infectious Diseases
02-Dec-2022	Aptamer Group announces new deals to support novel therapies and improved assays	Aptamer Group announces new deals to support novel therapies and improved assays
02-Dec-2022	Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors	Immunocore
01-Dec-2022	Quest for health accelerator launches in French Grand Est region with focus on healthcare start-ups	Andrew Lloyd Associates
01-Dec-2022	Avectas, CCRM and OmniaBio Expand their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE® Technology	Avectas
01-Dec-2022	Pronalyse’s Fusion Protein Characterization Service Aids in the Drug Development Process	Creative Proteomics
01-Dec-2022	Creative Proteomics Lipidomics Launches Ceramides Analysis Service	Creative Proteomics
01-Dec-2022	Creative Proteomics Metabolomics Unveils Drug-Resistant Metabolomics Research Service	Creative Proteomics
30-Nov-2022	Bayer receives acceptance of Kerendia® ▼ (finerenone) by Scottish Medicines Consortium (SMC) for treating adult patients with chronic kidney disease associated with type 2 diabetes in NHS Scotland	Bayer
29-Nov-2022	BioWin expands its ‘Growth & Financing’ member service by appointing two industry experts	Andrew Lloyd Associates
29-Nov-2022	Creative Enzymes Expands Its Service Offering with the Launch of Custom Enzyme Blends	Creative Enzymes
29-Nov-2022	Creative Enzymes Provides DNA Molecular Weight Markers and Ladders	Creative Enzymes
29-Nov-2022	EverImmune appoints Prof. Laurence Zitvogel as president of scientific advisory board	Andrew Lloyd Associates
29-Nov-2022	Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team	Rewind Therapeutics
29-Nov-2022	CD Genomics Expands Its Sequencing Portfolio with the Launch of Whole Exome Sequencing	CD Genomics